PITAVASTATIN MAGNESIUM - Generic Drug Details

What are the generic sources for pitavastatin magnesium and what is the scope of patent protection?

Pitavastatin magnesium is the generic ingredient in one branded drug marketed by Medicure and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Pitavastatin magnesium has two patent family members in two countries.

There is one drug master file entry for pitavastatin magnesium. Two suppliers are listed for this compound.

Summary for PITAVASTATIN MAGNESIUM

International Patents:	2
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	3
What excipients (inactive ingredients) are in PITAVASTATIN MAGNESIUM?	PITAVASTATIN MAGNESIUM excipients list
DailyMed Link:	PITAVASTATIN MAGNESIUM at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PITAVASTATIN MAGNESIUM

Constraining patent/regulatory exclusivity:

8,829,186

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for PITAVASTATIN MAGNESIUM

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for PITAVASTATIN MAGNESIUM

C10AA	HMG CoA reductase inhibitors
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for PITAVASTATIN MAGNESIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-001	Jul 14, 2017		DISCN	Yes	No	8,829,186		Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-002	Jul 14, 2017		RX	Yes	No	8,829,186		Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-003	Jul 14, 2017		RX	Yes	Yes	8,829,186		Y	Y

International Patents for PITAVASTATIN MAGNESIUM

Country	Patent Number	Title	Estimated Expiration
Japan	2013516459
World Intellectual Property Organization (WIPO)	2011089623

PITAVASTATIN MAGNESIUM Market Analysis and Financial Projection

Last updated: February 12, 2026

Market Dynamics for Pitavastatin Magnesium

Pitavastatin magnesium, marketed primarily as LIVALO, is a statin used to lower LDL cholesterol and prevent cardiovascular disease. The drug holds a unique position within the statin class due to its pharmacokinetic profile and tolerability.

Market Overview and Growth Drivers

The global statin market was valued at approximately $12 billion in 2022 and is projected to reach $16 billion by 2030, with a CAGR of roughly 4.1% [1]. Pitavastatin, responsible for about 3% of this market, is growing at a faster rate driven by its favorable tolerability and efficacy profile, especially in Japan and emerging markets.

Key Factors Influencing Market Dynamics

• Regulatory Approvals: Approved in Japan (2003), the U.S. (2018 as LIVALO), and other regions. Approval timelines influence market penetration.
• Patent Status: Patents expired in some regions, leading to generic competition, but exclusivity remains in key markets until 2025.
• Physician Preference: Cardiologists favor pitavastatin for its fewer drug-drug interactions and lower risk of hepatic side effects compared to other statins.
• Patient Demographics: Aging populations in North America and Asia increase demand for lipid-lowering therapies.
• Competitive Landscape: Dominance by atorvastatin and rosuvastatin; pitavastatin faces competition but maintains niche due to tolerability.

Regional Insights

• Japan: The primary market with over 70% of global sales, driven by high cardiovascular disease prevalence and established physician familiarity.
• United States: Gained approval in 2018, with growth limited by existing generic statins, but expanding due to unique pharmacokinetics.
• Emerging Markets: Rapid uptake owing to lower cost and favorable tolerability profile.

Financial Trajectory of Pitavastatin Magnesium

Revenue Trends

• Historical Sales: Estimated global sales of LIVALO reached $350 million in 2022, with Japan accounting for approximately 80%. The U.S. contributed around $70 million following its 2018 approval.
• Forecasted Growth: Projected to grow at a CAGR of 6–8% through 2025, driven by expanding indications, market penetration in emerging regions, and increased physician acceptance.

Year	Estimated Sales (USD millions)	Notes
2022	350	Strong presence in Japan, initial U.S. uptake
2023	375	Growth via market expansion
2024	410	Increased awareness, expanded indications
2025	440	Potential entry into additional lipid management markets

Pricing Strategies

LIVALO's pricing varies regionally, with premium pricing in Japan (~$3–4 per tablet) and more competitive pricing in North America (~$2 per tablet). Price reductions in generics are expected post patent expiry, impacting revenue potential.

Profitability and R&D Investment

Profit margins are affected by manufacturing costs (~$0.50 per tablet), market competition, and reimbursement policies. Sales and marketing expenses in North America are estimated at 15–20% of revenue, influencing net profit.

Patent and Regulatory Outlook

Main patents expire in key markets by 2025, opening the market to generics. Regulatory approvals for new formulations or indications could extend revenue streams.

Market Risks and Opportunities

• Risks: Patent expiry leading to generic entry, pricing pressures, and stiff competition from well-established statins.
• Opportunities: New lipid management indications, combination therapies, and tailored dosing in specific populations can enhance market share.

Conclusion

Pitavastatin magnesium's market remains primarily driven by its niche positioning in Japan, with international expansion opportunities limited by competition and patent expirations. Its financial outlook is positive, with modest growth forecasts contingent on market penetration and pipeline developments.

---

Key Takeaways

• The global statin market is expanding, but pitavastatin's share remains relatively small (~3%), with growth driven by its tolerability and pharmacokinetic profile.
• Japan continues as the dominant market; the U.S. contribution remains modest following 2018 approval.
• Sales are expected to grow at a CAGR of 6–8% through 2025 but face headwinds from patent expiries and generic competition.
• Revenue projections suggest sales could reach approximately $440 million by 2025, contingent on market expansion and regulatory developments.
• Post-patent expiry, generics will threaten current pricing structures, pressuring profit margins.

---

FAQs

1. What factors differentiate pitavastatin magnesium from other statins?
It exhibits fewer drug-drug interactions and has a lower risk of hepatic side effects, making it suitable for patients with polypharmacy and hepatic concerns.

2. When do key patents on LIVALO expire?
Main patents in the U.S. and Europe expire around 2025, opening the market for generics.

3. How does the market share of pitavastatin compare to atorvastatin?
Atorvastatin holds more than 70% of the overall statin market, while pitavastatin's share is about 3%, primarily in Japan.

4. How are pricing strategies influencing revenue?
Premium pricing in Japan sustains high margins, while discounting in the U.S. and emerging markets limits revenue but increases volume.

5. What growth opportunities exist for pitavastatin?
Potential indications for broader lipid management, combination therapies, and entering new markets may support growth post-patent expiry.

---

References

[1] Statin Market Analysis, Global Market Insights, 2022.